## APPENDIX II

Source: <u>Legal</u> > / . . . / > Utility, Design and Plant Patents [i]

Terms: claims (pharmaceutically acceptable w/2 ester thereof) and date(geq (01/01/1999) and leq
(11/01/1999)) (<u>Edit Search</u> | <u>Suggest Terms for My Search</u>)

**F**Select for FOCUS™ or Delivery

5972898 October 26, 1999 , 3',3-N-bis-substituted macrolide LHRH antagonists, Sauer, Daryl R. - Trevor, Wisconsin, United States (US); Haviv, Fortuna - Deerfield, Illinois, United States (US); Randolph, John - Mundelein, Illinois, United States (US); Mort, Nicholas A. - Waukegan, Illinois, United States (US); Dalton, Christopher R. - Mundelein, Illinois, United States (US); Bruncko, Milan - Lake Bluff, Illinois, United States (US); Kaminski, Michele A. - Beach Park, Illinois, United States (US); Crawford, Bradley W. - Gurnee, Illinois, United States (US); Frey, Lisa Marie - Mundelein, Illinois, United States (US); Greer, Jonathan - Chicago, Illinois, United States (US), 049458 (09), March 22, 1999 - ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., ABBOTT LABORATORIES CHAD 0377/AP6D-2 100 ABBOTT PARK ROADABBOTT PARK, ILLINOIS, 60064, Reel and Frame Number: 009839/0939, Abbott Laboratories, Abbott Park, Illinois, United States (US), United States company or corporation (02)

**CORE TERMS:** sub, compound, sup, carbamate, cyclic, meoh, mmol, delta, substituting, atom ...

- ... formula: ##STR42## or a **pharmaceutically acceptable** salt or **ester** thereof, wherein A is selected from the group ... ... formula: ##STR43## or a **pharmaceutically acceptable** salt or **ester** thereof, wherein A is selected from the group ...
- 5972896, October 26, 1999, Antiangiogenic peptides and methods for inhibiting angiogenesis, Davidson, Donald J. Gurnee, Illinois, United States (US), 131995 (09), Abbott Laboratories, Abbott Park, Illinois, United States (US), United States company or corporation (02)

**CORE TERMS:** peptide, sup, kringle, fragment, cell, amino acid, sub, sequence, gene, compound ...

- ... Y (I) or a **pharmaceutically acceptable** salt, **ester** or prodrug thereof, wherein A is absent or ...
- ... Y (II), or a **pharmaceutically acceptable** salt, **ester** or prodrug thereof, wherein A is absent or ...
- ... Y (I) or a **pharmaceutically acceptable** salt, **ester** or prodrug thereof, wherein A is absent or ...
- 3. 5968942, October 19, 1999, .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors, Vazquez, Michael L. Gurnee, Illinois, United States (US); Mueller, Richard A. Glencoe, Illinois, United States (US); Talley, John J. Brentwood, Missouri, United States (US); Getman, Daniel P. Chestertfield, Missouri, United States (US); DeCrescenzo, Gary A. St. Peters, Missouri, United States (US); Freskos, John N. Clayton, Missouri, United States (US); Bertenshaw, Deborah E. Brentwood, Missouri, United States (US); Heintz, Robert M. Ballwin, Missouri, United States (US), 294468 (08), October 31, 1994 ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., G.D. SEARLE & CO. CORPORATE PATENT DEPARTMENT 5200 OLD ORCHARD ROAD SKOKIE, IL 60077, G.D. SEARLE & CO. CORPORATE PATENT DEPARTMENT 5200 OLD ORCHARD ROAD SKOKIE, IL 60077, Reel and Frame Number: 007254/0618, G. D. Searle & Co., Chicago, Illinois, United States (US), United States company or corporation (02), July 13,

2006 - CHANGE OF NAME (SEE DOCUMENT FOR DETAILS)., G.D. SEARLE LLC 1209 ORANGE STREET WILMINGTON DELAWARE 19801, Reel and Frame Number: 017921/0735

**CORE TERMS:** sub, mmol, sup, acid, ethyl acetate, concentrated, preparation, compound, room temperature, filtered ...

- ... claim 2 or a **pharmaceutically acceptable** salt or **ester** thereof, wherein R.sup.2 is an ...
- ... claim 3 or a **pharmaceutically acceptable** salt or **ester** thereof, wherein R.sup.2 is an ...
- ... claim 4 or a **pharmaceutically acceptable** salt or **ester** thereof, wherein R.sup.2 is an ...
- ... claim 5 or a **pharmaceutically acceptable** salt or **ester** thereof, wherein R.sup.2 is ...
- ... formula: ##STR834## or a **pharmaceutically acceptable** salt or **ester** thereof, wherein R.sup.2 is an ...
- ... claim 17 or a **pharmaceutically acceptable** salt or **ester** thereof, wherein R.sup.2 is an ...
- ... formula: ##STR836## or a **pharmaceutically acceptable** salt or **ester** thereof, wherein A is a phenyl or ...
- 4. <u>5968937</u>, October 19, 1999, Tricyclic diazepine vasopressin antagonists and oxytocin antagonists, Albright, Jay Donald Nanuet, New York, United States (US); Reich, Marvin Fred Suffern, New York, United States (US); Delos Santos, Efren Guillermo Nanuet, New York, United States (US), 207522 (09), American Cyanamid Company, Madison, New Jersey, United States (US), United States company or corporation (02), May 14, 2003 CHANGE OF NAME (SEE DOCUMENT FOR DETAILS)., WYETH HOLDINGS CORPORATION FIVE GIRALDA FARMSMADISON, NEW JERSEY, 07940, Reel and Frame Number: 014043/0323

**CORE TERMS:** sub, mixture, vacuo, chloride, residue, stirred, sup, washed, dried, filtered ...

- ... C.sub.3); and the **pharmaceutically acceptable** salts, **esters** and pro-drug forms thereof. ...
- ... claim 1, or a **pharmaceutically acceptable** salt, **ester** or prodrug form thereof, and a ...
- $\dots$  claim 1, or a **pharmaceutically acceptable** salt, **ester** or prodrug form thereof, and a  $\dots$
- 5. <u>5968930</u>, October 19, 1999, Tricyclic diazepine vasopressin antagonists and oxytocin antagonists, Albright, Jay Donald Nanuet, New York, United States (US); Reich, Marvin Fred Suffern, New York, United States (US); Delos Santos, Efren Guillermo Nanuet, New York, United States (US), 999830 (08), American Cyanamid Company, Madison, New Jersey, United States (US), United States company or corporation (02), May 14, 2003 CHANGE OF NAME (SEE DOCUMENT FOR DETAILS)., WYETH HOLDINGS CORPORATION FIVE GIRALDA FARMSMADISON, NEW JERSEY, 07940, Reel and Frame Number: 014043/0323

**CORE TERMS:** sub, mixture, vacuo, chloride, residue, stirred, sup, washed, dried, filtered ...

- ... C.sub.3); and the **pharmaceutically acceptable** salts, and **ester.** 2. The compound according to ...
- ... claim 1, or a pharmaceutically acceptable salt or ester thereof, and a

suitable pharmaceutical ...

6. <u>5968908</u>, October 19, 1999, Restricted 9-cis retinoids, Epstein, Joseph William - Monroe, New York, United States (US); Qing, Feng Ling - Shanghai, China (CN); Birnberg, Gary Harold - Monroe, New York, United States (US); Gilbert, Adam Matthew - Valley Cottage, New York, United States (US), 542146 (08), April 19, 1999 - ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., AMERICAN CYANAMID COMPANY FIVE GIRALD FARMSMADISON, NEW JERSEY, 07940, Reel and Frame Number: 009902/0272, American Cyanamid Company, Madison, New Jersey, United States (US), United States company or corporation (02), May 14, 2003 - CHANGE OF NAME (SEE DOCUMENT FOR DETAILS)., WYETH HOLDINGS CORPORATION FIVE GIRALDA FARMSMADISON, NEW JERSEY, 07940, Reel and Frame Number: 014043/0323

**CORE TERMS:** sub, acid, compound, mixture, sup, formula, tetrahydrofuran, ethyl, stirred, hydrogen ...

- ... ring of the formula: ##STR62## and the **pharmaceutically acceptable** salts and **esters.** 2. A compound of ...
- ... pyridylmethyl; Y is hydrogen, and the **pharmaceutically acceptable** salts and **esters.** 3. A compound of ...
- ... pyridylmethyl; Y is hydrogen, and the **pharmaceutically acceptable** salts and **esters.** 4. A compound of ...
- ... pyridylmethyl; Y is hydrogen, and the **pharmaceutically acceptable** salts and **esters.** 5. A compound ...
- 7. 5965607, October 12, 1999, Substituted Benzo1,4!dioxines as antiobesity agents, Venkatesan, Aranapakam M. Rego Park, New York, United States (US), 993481 (08), May 4, 1999 ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., AMERICAN HOME PRODUCTS CORPORATION FIVE GIRALDA FARMSMADISON, NEW JERSEY, 07940, Reel and Frame Number: 009951/0695, American Home Products Corporation, Madison, New Jersey, United States (US), United States company or corporation (02), May 1, 2002 CHANGE OF NAME (SEE DOCUMENT FOR DETAILS)., WYETH FIVE GIRALDA FARMSMADISON, NEW JERSEY, 07940, Reel and Frame Number: 012822/0248

**CORE TERMS:** sup, sub, compound, acid, beta, dioxine-2, alkyl, hydrogen, ester, receptor ...

- ... dicarboxylic acid diisopropyl **ester** or a **pharmaceutically acceptable** salt thereof. 4. A ...
- ... acid 3-isopropyl **ester** or a **pharmaceutically acceptable** salt thereof. 5. A
- $\dots$  dicarboxylic acid dibutyl **ester** or a **pharmaceutically acceptable** salt thereof. 6. A  $\dots$
- ... 2-ethoxy-ethyl) **ester** or a **pharmaceutically acceptable** salt thereof. 7. A ...
- ... dicarboxylic acid diethyl **ester** or a **pharmaceutically acceptable** salt thereof. 8. A ...
- ... dicarboxylic acid dicyclohexyl **ester** or a **pharmaceutically acceptable** salt thereof. 9. A ...
- ... dicarboxylic acid dicyclopentyl **ester** or a **pharmaceutically acceptable** salt thereof. 10. A ...
- ... dicarboxylic acid dioctyl **ester** or a **pharmaceutically acceptable** salt thereof. 11. A ...
- ... dicarboxylic acid dibenzyl ester or a pharmaceutically acceptable salt

thereof. 12. A ...

8. <u>5965558</u>, October 12, 1999, Modulators of proteins with phosphotyrosine recognition units, Mjalli, Adnan - Escondido, California, United States (US); Sarshar, Sepehr - Cardiff by the Sea, California, United States (US); Cao, Xiaodong - Carlsbad, California, United States (US); Bakir, Farid - San Diego, California, United States (US), 960637 (08), Ontogen Corporation, Carlsbad, California, United States (US), United States company or corporation (02)

**CORE TERMS:** sub, compound, formula, alkyl, delta, protein, solvent, resin, dichloromethane, cd45 ...

October 12, 2003 - due to ...

- ... 11 alkyl substituent, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 2. A compound ...
- ... thienyl, furyl, pyridyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 3. A compound ...
- $\dots$  1 wherein aryl is phenyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 4. A compound  $\dots$
- ... 1 wherein aryl is naphthyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 5. A compound ...
- $\dots$  1 wherein aryl is biphenyl, or its **pharmaceutically acceptable** salts, or **esters,** thereof. 6. A compound  $\dots$
- ... 1 wherein aryl is thienyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 7. A compound ...
- ... 1 wherein aryl is furyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 8. A compound ...
- ... 1 wherein aryl is pyridyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 9. A compound with the ...
- ... 11 alkyl substituent, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 10. A compound ...
- ... thienyl, furyl, pyridyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 11. A compound ...
- ... 9 wherein aryl is phenyl, or its **pharmaceutically acceptable** salts, or **esters,** thereof. 12. A compound ...
- ... 9 wherein aryl is naphthyl, or its **pharmaceutically acceptable** salts, or **esters,** thereof. 13. A compound ...
- ... 9 wherein aryl is biphenyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 14. A compound ...
- ... 9 wherein aryl is thienyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 15. A compound ...
- ... 9 wherein aryl is furyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof. 16. A compound ...
- ... 9 wherein aryl is pyridyl, or its **pharmaceutically acceptable** salts, or **esters**, thereof.
- 9. <u>5962526</u>, October 5, 1999, Pharmaceutical compositions containing hydroxycarboxylic acids and/or ketocarboxylic acids and methods of using same, Yu, Ruey J. Ambler, Pennsylvania, United States (US); Van Scott, Eugene J. Rydal, Pennsylvania, United States (US), 926030 (08), December 10, 1998 ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., TRISTRATA TECHNOLOGY, INC. 4 RESEARCH WAYPRINCETON, NEW JERSEY, 08540, Reel and Frame Number: 009733/0530 December 10, 1998 ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., TRISTRATA, INCORPORATED 4 RESEARCH WAYPRINCETON, NEW JERSEY, 08540, Reel and Frame Number: 009733/0533, Tristrata Technology, Inc., Wilmington,

Delaware, United States (US), United States company or corporation (02)

CORE TERMS: acid, sub, composition, skin, gram, formulated, hydroxyacid, therapeutic, lactic acid, dissolved ...

- ... a free acid, ester, lactone, pharmaceutically acceptable salt thereof, or an isomer selected from ...
- ... a free acid, ester, lactone, pharmaceutically acceptable salt thereof, or an isomer selected from ...
- ... a free acid, ester, lactone, pharmaceutically acceptable salt thereof, or an isomer selected from ...
- 10. 5962440, October 5, 1999, Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method, Sulsky, Richard B. - West Trenton, New Jersey, United States (US), 175180 (09), October 20, 1998 - ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., BRISTOL-MYERS SQUIBB COMPANY P.O. BOX 4000PRINCETON, NEW JERSEY, 08543, Reel and Frame Number: 009522/0681, Bristol-Myers Squibb Company, Princeton, New Jersey, United States (US), United States company or corporation (02)

CORE TERMS: sup, sub, compound, alkyl, mmol, aryl, heteroaryl, carbon, cycloalkyl, independently ...

... carboxamide; or an N-oxide thereof, or pharmaceutically acceptable salts thereof or **esters** thereof. 11. The compound as ...

Source: Legal > / . . . / > Utility, Design and Plant Patents []

Terms: claims (pharmaceutically acceptable w/2 ester thereof) and date(geq (01/01/1999) and leq

(11/01/1999)) (Edit Search | Suggest Terms for My Search)

View: Cite

Date/Time: Tuesday, December 26, 2006 - 4:40 PM EST



About LexisNexis | Terms & Conditions LexisNexis® Copyright © 2006 LexisNexis, a division of Reed Elsevier Inc. All rights